Scholars Central

Conference abstract

Production of Drugloaded Nano- and Microparticle Formulations with ImSus? Platform Technology

Authors: Celal Albayrak

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

mSus? is a unique platform technology for the manufacture of drug-loaded polymeric nano- and microparticle formulations, which can be administered via diff erent routes. ImSus? is a fast, simple and robust one pot process; all excipients used are either approved by the FDA for parenteral applications or generally regarded as safe (GRAS). Due to the new physical principle behind ImSus ? technology, the formulations show no initial burst as well as very high drug loading and encapsulation effi ciency. Using ImSus ? technology it was succeeded to develop the fi rst microparticlebased controlled-release depot forms of goserelin-acetate, a drug that is mainly indicated for the treatment of hormone-related cancers like prostate cancer. Th e current dosage forms of goserelin-acetate - AstraZeneca?s Zoladex ? 3.6 mg or 10.8 mg for treatment periods of one month or three months, respectively - are implants, which are administered via large needle gauges (16G or 14G). Th e new microparticle-based depot forms (both, the one-month and the threemonth product) shall be administered via a signifi cantly smaller needle gauge (25G), the smallest in its class. Th is will increase the patient compliance and convenience. In addition, the new depot forms will compete with current depot forms of leuprorelinacetate and triptorelin-acetate, drugs of the same class that are equivalently indicated. Th ough most of these competitors are likewise marketed as microparticle-based depot forms, only the new form allows for the manufacture without using carcinogenic solvents. Extensive pre-clinical data from comparative animal studies will be presented that demonstrates equivalent or even superior pharmacodynamic profi les (testosterone suppression).

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutica Analytica Acta
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Celal Albayrak”